Angelini Pharma SpA - Company Profile
Powered by 
All the sales intelligence you need on Angelini Pharma SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Angelini Pharma SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Angelini Pharma SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Angelini Pharma Spa (Angelini Pharma) manufactures, markets, and commercializes pharmaceutical and healthcare products. The company operates in prescription and over-the-counter (OTC) pharmaceutical sectors with a focus on pain and inflammation disorders, traveler's diarrhea, infection control and infectious diseases, bacterial infections, mental health, and central nervous system diseases and disorders. Its products include benzydamine, trazodone, paracetamol, progesterone, glycerin, tetrahydrozoline, lactitol and prulifloxacin, among others. The company offers its products through brands such as Andolex, Trittico, Aulin, Tachipirina, Tantum, Lono, Vantal to Hospitals, Research Centers, Pharma Biotech and Contract Research Organizations. It operates manufacturing facilities in Italy, Spain, and the US. Angelini Pharma is headquartered in Rome, Italy.
Headquarters
Italy
Address
Viale Amelia 70, Rome, Lazio, 00181
Website
www.angelinipharma.com
No of Employees
3,000
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$1.3B
Angelini Pharma SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Benzydamine | Andolex |
| Trazodone | Trittico |
| Paracetamol | Aulin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired Catalyst Pharmaceuticals Inc. |
| 2026 | Contracts/Agreements | In February, the company entered into a strategic research collaboration and licensing agreement with Quiver Bioscience to discover and advance novel therapeutics for genetic epilepsies. |
| 2025 | Contracts/Agreements | In September, the company entered into an agreement with Sovargen to license global development and commercialization rights for innovative brain health asset. |
Competitor Comparison
| Key Parameters | Angelini Pharma SpA | A. Menarini Industrie Farmaceutiche Riunite Srl | Chiesi Farmaceutici SpA | Alfasigma SpA | Shedir Pharma Srl |
|---|---|---|---|---|---|
| Headquarters | Italy | Italy | Italy | Italy | Italy |
| City | Rome | Florence | Parma | Bologna | Mercato San Severino |
| State/Province | Lazio | Toscana | Emilia-Romagna | Emilia-Romagna | - |
| No. of Employees | 3,000 | 17,800 | 7,686 | 4,000 | 93 |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sergio Marullo di Condojanni | Chief Executive Officer | Senior Management | 2026 | - |
| Massimo Marin | Chief Strategy Officer; Chief Financial Officer | Senior Management | 2025 | - |
| Enrica Dogali | Chief Compliance Officer; Chief Privacy Officer; Chief Legal Officer | Senior Management | 2020 | - |
| Roberto Scrivo | Chief Communication Officer; Chief External Affairs Officer; Chief Sustainability Officer | Senior Management | 2026 | - |
| Agnese Cattaneo | Chief Medical Officer | Senior Management | 2017 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer